Static respiratory system compliance (Crs) 
Curosurf is a preparation of polar lipids, isolated from minced pigs lungs. It contains approximately 99% lipids, mainly phospholipids, and 1% low molecular weight hydrophobic apoproteins SP-B and SP-C.14 Infants were randomly assigned to receive either 1-25 or 2-5 ml/kg body weight (100 mg or 200 mg/kg) with the aim of achieving rapid distribution throughout the lung. Half was delivered into each main bronchus by positioning the infant on one side before instilling the surfactant intratracheally and continuing mechanical ventilation in that position for one minute. The procedure was then repeated on the opposite side. Exosurf is a synthetic surfactant which contains 13-5 mg/ml of dipalmitoyl phosphatidyl choline, 1 5 mg/ml cetyl alcohol, 1 mg/ml tyloxapol in 0-1 N sodium chloride and no surfactant apoproteins.2 Over approximately 20-30 minutes 5 ml/kg was administered into the proximal endotracheal tube. The infants remained supine and mechanical ventilation continued throughout. Exosurf was . . (table 2) . The infants with initial values of static Crs suggesting surfactant deficiency (< 1 *8 ml/cm H20/m) who received Exosurf had slightly greater ventilation requirements (VEI) before treatment than those treated with Curosurf. There were 15 infants whose static Crs before treatment was not consistent with surfactant deficiency (-1-8 mi/cm H2O/m). They were significantly heavier, longer, easier to ventilate, older at time of treatment, and of later gestation than those whose initial Crs was consistent with surfactant deficiency.
The changes in Crs, oxygen requirements, and VEI seen after treatment are shown in figs 1 and 2. Of the 58 infants with initial Crs <1-8 mi/cm H20/m (fig 1) those treated with Curosurf showed a median improvement in Crs of 18% (p=0-002) three hours after treatment increasing to 39% (p=0-0001) at 12 hours. These changes were accompanied by significant improvements in oxygenation and VEI at both three and 12 hours. The infants treated with Exosurf showed no statistically significant changes in Crs at three or 12 hours, with median changes of -6-2% (p=0.24) at three hours and +5% (p=0-28) at 12 hours. Their oxygen requirements were significantly lower at three hours than before treatment but the VEI did not improve until 12 hours. The median reduction in oxygen requirement was greater after Curosurf than Exosurf both at three hours (change in FiO2 -0-32 compared with -0-11; p<0-001) and at 12 hours (change in FIo2 -0-32 compared with -0-13; p<0-005) after treatment. If the Crs results for these infants are expressed in absolute terms rather than as percentage changes, the same pattern is observed with median pretreatment Crs for the Curosurf treated infants of 1-1 mi/cm H20/m and median change at three hours +0-2 (p=0-0037), and median pretreatment Crs for the Exosurf treated infants 1-1 mi/cm H20/m and median change at three hours Of the 15 infants with initial Crs 3 ml/cm H20/m (fig 2) 
